Supporting the use of CSF biomarkers for early diagnosis, decreased Aβ42 and increased T-tau and P-tau are seen in patients with mild cognitive impairment (MCI) later diagnosed with AD. The gene discussed is MAPT; the disease is Cognitive impairment.